Pintado C - Search Results

1

Acute Hepatitis B Infection After a Switch to Long-Acting Cabotegravir and Rilpivirine.

Pintado C, Delaugerre C, Molina JM. Pintado C, et al. Open Forum Infect Dis. 2020 Sep 25;7(9):ofaa367. doi: 10.1093/ofid/ofaa367. eCollection 2020 Sep. Open Forum Infect Dis. 2020. PMID: 33005698 Free PMC article.

2

Predictive values of the human immunodeficiency virus phenotype and genotype and of amprenavir and lopinavir inhibitory quotients in heavily pretreated patients on a ritonavir-boosted dual-protease-inhibitor regimen.

Barrail-Tran A, Morand-Joubert L, Poizat G, Raguin G, Le Tiec C, Clavel F, Dam E, Chêne G, Girard PM, Taburet AM; Puzzle-1 (ANRS 104) Study Group. Barrail-Tran A, et al. Antimicrob Agents Chemother. 2008 May;52(5):1642-6. doi: 10.1128/AAC.01314-07. Epub 2008 Feb 19. Antimicrob Agents Chemother. 2008. PMID: 18285478 Free PMC article. Clinical Trial.

3

HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro.

Roquebert B, Damond F, Collin G, Matheron S, Peytavin G, Bénard A, Campa P, Chêne G, Brun-Vézinet F, Descamps D; French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2). Roquebert B, et al. J Antimicrob Chemother. 2008 Nov;62(5):914-20. doi: 10.1093/jac/dkn335. Epub 2008 Aug 20. J Antimicrob Chemother. 2008. PMID: 18718922

4

[Follow-up with the assistance of TB-info software of 208 tuberculosis patients who were treated in 2004].

Bourgarit A, Mallet HP, Keshtmand H, De Castro N, Rambeloarisoa J, Fain O, Antoun F, Picard C, Rocher G, Che D, Farge D; pour TB-info. Bourgarit A, et al. Rev Med Interne. 2009 Oct;30(10):841-6. doi: 10.1016/j.revmed.2009.03.362. Epub 2009 Apr 29. Rev Med Interne. 2009. PMID: 19406537 French.

5

Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy.

Delaugerre C, Flandre P, Chaix ML, Ghosn J, Raffi F, Dellamonica P, Jaeger H, Shürmann D, Cohen-Codar I, Van PN, Norton M, Taburet AM, Delfraissy JF, Rouzioux C; MONARK Study Group. Delaugerre C, et al. Antimicrob Agents Chemother. 2009 Jul;53(7):2934-9. doi: 10.1128/AAC.01643-08. Epub 2009 May 18. Antimicrob Agents Chemother. 2009. PMID: 19451297 Free PMC article. Clinical Trial.

6

Burden of HIV disease and comorbidities on the chances of maintaining employment in the era of sustained combined antiretoviral therapies use.

Dray-Spira R, Legeai C, Le Den M, Boué F, Lascoux-Combe C, Simon A, May T, Goujard C, Meyer L; ANRS-COPANA Cohort Study Group. Dray-Spira R, et al. AIDS. 2012 Jan 14;26(2):207-15. doi: 10.1097/QAD.0b013e32834dcf61. AIDS. 2012. PMID: 22008658 Free PMC article.

7

Immune deficiency could be an early risk factor for altered insulin sensitivity in antiretroviral-naive HIV-1-infected patients: the ANRS COPANA cohort.

Boufassa F, Goujard C, Viard JP, Carlier R, Lefebvre B, Yeni P, Bouchaud O, Capeau J, Meyer L, Vigouroux C; ANRS COPANA Cohort Study Group. Boufassa F, et al. Antivir Ther. 2012;17(1):91-100. doi: 10.3851/IMP1916. Antivir Ther. 2012. PMID: 22267473 Free PMC article.

8

Continuous versus intermittent treatment strategies during primary HIV-1 infection: the randomized ANRS INTERPRIM Trial.

Goujard C, Emilie D, Roussillon C, Godot V, Rouzioux C, Venet A, Colin C, Pialoux G, Girard PM, Boilet V, Chaix ML, Galanaud P, Chene G; ANRS-112 INTERPRIM Study Group. Goujard C, et al. AIDS. 2012 Sep 24;26(15):1895-905. doi: 10.1097/QAD.0b013e32835844d9. AIDS. 2012. PMID: 22842994 Clinical Trial.

9

Role and evolution of viral tropism in patients with advanced HIV disease receiving intensified initial regimen in the ANRS 130 APOLLO trial.

Charpentier C, Joly V, Larrouy L, Fagard C, Visseaux B, de Verdière NC, Raffi F, Yeni P, Descamps D; ANRS 130 APOLLO Trial Study Group. Charpentier C, et al. J Antimicrob Chemother. 2013 Mar;68(3):690-6. doi: 10.1093/jac/dks455. Epub 2012 Nov 14. J Antimicrob Chemother. 2013. PMID: 23152480 Clinical Trial.

10

Transmitted drug resistance in French HIV-2-infected patients.

Charpentier C, Visseaux B, Bénard A, Peytavin G, Damond F, Roy C, Taieb A, Chêne G, Matheron S, Brun-Vézinet F, Descamps D; ANRS CO5 HIV-2 Cohort. Charpentier C, et al. AIDS. 2013 Jun 19;27(10):1671-4. doi: 10.1097/QAD.0b013e32836207f3. AIDS. 2013. PMID: 23595155

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

126 results

Search Page